NCT02390258View on ClinicalTrials.gov

Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103

PHASE1CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Atrial Fibrillation
Interventions
DRUG

10mg XEN-D0103

DRUG

Placebo

DRUG

30mg XEN-D0103

DRUG

60mg XEN-D0103

DRUG

120mg XEN-D0103

DRUG

200mg XEN-D0103

DRUG

150mg XEN-D0103

Trial Locations (1)

M15 6SH

ICON Development Solutions, Manchester

All Listed Sponsors
lead

Xention Ltd

INDUSTRY

NCT02390258 - Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103 | Biotech Hunter | Biotech Hunter